Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Americas has been experiencing steady growth in recent years.
Customer preferences: One of the main factors driving the growth of this market is the increasing prevalence of hypertension in the region. As a result, there is a growing demand for effective anti-hypertensive drugs. Additionally, with an aging population and the rise in lifestyle-related diseases, there is a greater need for pharmaceutical interventions to manage hypertension.
Trends in the market: The United States is the largest market for anti-hypertensive drugs in the Americas, with a significant portion of the population suffering from hypertension. In recent years, there has been a shift towards combination therapies, where patients are prescribed multiple drugs to manage their hypertension. This has led to an increase in the number of fixed-dose combination drugs available in the market.In Latin America, Brazil and Mexico are the largest markets for anti-hypertensive drugs. However, the market is more fragmented in these countries, with a larger number of local players competing with multinational pharmaceutical companies. In these markets, there is a growing trend towards the use of generic drugs, as they are more affordable and accessible to a larger population.
Local special circumstances: In Canada, the government plays a significant role in regulating the pharmaceutical industry, which has led to a more stable market for anti-hypertensive drugs. The government negotiates drug prices with pharmaceutical companies, which helps to keep costs down for consumers. Additionally, there is a growing trend towards personalized medicine, where patients are prescribed drugs based on their individual genetic makeup.
Underlying macroeconomic factors: The healthcare industry in the Americas is highly regulated, with strict rules governing the approval and marketing of pharmaceutical products. However, there is also a growing trend towards innovation in the industry, with pharmaceutical companies investing heavily in research and development to bring new and more effective drugs to market. The increasing prevalence of hypertension in the region, coupled with an aging population and the rise in lifestyle-related diseases, is expected to continue driving growth in the anti-hypertensive drugs market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
